Cargando…

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy

The promising treatment combination of ionizing radiation (IR) with a hypoxia-activated prodrug (HAP) is based on biological cooperation. Here we investigated the hypoxia-activated prodrug evofosfamide in combination with different treatment regimens of IR against lung A549- and head&neck UT-SCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nytko, Katarzyna J., Grgic, Ivo, Bender, Sabine, Ott, Janosch, Guckenberger, Matthias, Riesterer, Oliver, Pruschy, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410338/ https://www.ncbi.nlm.nih.gov/pubmed/28423594 http://dx.doi.org/10.18632/oncotarget.15784

Ejemplares similares

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model()()
por: Hajj, Carla, et al.
Publicado: (2017)

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer
por: Yoon, Jeesun, et al.
Publicado: (2021)

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide
por: Lüpfert, Christian, et al.
Publicado: (2018)

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Larue, Ruben T. H. M., et al.
Publicado: (2016)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

Interfering with Tumor Hypoxia for Radiotherapy Optimization
por: Telarovic, Irma, et al.
Publicado: (2021)

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
por: Brenner, Andrew J., et al.
Publicado: (2021)

Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer
por: Britschgi, Christian, et al.
Publicado: (2018)

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models
por: Harms, Julia K., et al.
Publicado: (2019)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

(18)F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
por: Grkovski, Milan, et al.
Publicado: (2018)

The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Non–Small Cell Lung Cancer for Radiotherapy
por: Tschanz, Fabienne, et al.
Publicado: (2021)

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
por: Jamieson, Stephen M.F., et al.
Publicado: (2023)

Combined CT radiomics of primary tumor and metastatic lymph nodes improves prediction of loco-regional control in head and neck cancer
por: Bogowicz, Marta, et al.
Publicado: (2019)

Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma
por: Jardim-Perassi, Bruna V., et al.
Publicado: (2021)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Switching-on Prodrugs Using Radiotherapy
por: Geng, Jin, et al.
Publicado: (2021)

Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape
por: Hamis, Sara, et al.
Publicado: (2020)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study
por: Riesterer, Oliver, et al.
Publicado: (2011)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs
por: Aiyappa‐Maudsley, Radhika, et al.
Publicado: (2022)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model
por: Telarovic, Irma, et al.
Publicado: (2022)

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
por: Wojtkowiak, Jonathan W, et al.
Publicado: (2015)

The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy
por: Sun, Xiurong, et al.
Publicado: (2021)

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
por: Phillips, Roger M.
Publicado: (2016)

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
por: Hunter, Francis W, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7ic844ugimvl96df5nqhp75073